Eupraxia Pharmaceuticals is trading $6.82 (+5.25%) after second-quarter 2026 EPS of $(0.23) beat the $(0.25) consensus estimate.
- Reported a $14.5 million net loss, while substantial liquidity is expected to fund operations into the second half of 2028
- Extended cash runway and the earnings beat likely underpin after-hours buying
- Management expects interim RESOLVE Phase 2b data in Q4 2026; the regular session closed at $6.48, down 3.28% on August 12, 2026